An observational study in Primary Central Nervous System Lymphoma (PCNSL), sponsored by Xiaohui Ren. Recruiting at 3 sites in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Xiaohui Ren · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL). The study will primarily enroll patients undergoing needle biopsy or surgical resection of lesions involving the brain, spinal cord, or meninges, with a pathological diagnosis of central nervous system lymphoma. To ensure population homogeneity, patients with PCNSL will constitute the core analysis cohort. Patients with imaging findings suggestive of PCNSL but a final pathological diagnosis other than PCNSL will serve as disease controls, and matched healthy volunteers will be recruited as baseline controls.
At baseline, biopsy tissue, cerebrospinal fluid (CSF), peripheral blood, urine, saliva, and stool samples will be collected. Follow-up visits will be scheduled at 1 month after biopsy and every 3-6 months thereafter, with contrast-enhanced brain magnetic resonance imaging (MRI) and serial collection of CSF and peripheral blood. After the requirements of routine pathological diagnosis have been met, biopsy specimens will undergo tiered multi-omics profiling according to sample availability and freshness, including whole-exome sequencing, bulk RNA sequencing, single-cell RNA sequencing, metabolomics, spatial transcriptomics, and spatial metabolomics. Analyses of CSF and blood samples will focus on circulating tumor DNA and cell-free RNA (ctDNA/cfRNA), supplemented by conventional cytology, flow cytometry, and other clinical data for longitudinal disease monitoring.
The project will develop an integrated database incorporating clinical, imaging, pathological, molecular, and biospecimen data. It will characterize the relationships of baseline tissue multi-omics features and longitudinal changes in CSF- and blood-derived ctDNA/cfRNA with treatment response, recurrence prediction, and prognosis. The study will also develop diagnostic and risk-stratification models applicable to patients at our institution, across the region, and potentially throughout mainland China, while establishing standardized operating procedures for biospecimen collection and processing. This work is expected to provide high-quality evidence and a sustainable translational research platform for elucidating the biological heterogeneity of PCNSL, validating liquid-biopsy biomarkers, and optimizing precision follow-up strategies.
Xiaohui Ren is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be drawn from patients evaluated for suspected primary central nervous system lymphoma at participating tertiary referral hospitals in mainland China, including Beijing Tiantan Hospital, Shandong Provincial Hospital, and Tianjin Huanhu Hospital. Participants will be identified through departments of neurosurgery, hematology, neuro-oncology, radiology, and pathology. Healthy controls will be recruited from the participating institutions and surrounding communities to provide reference biospecimens and molecular profiles. The study will include a core PCNSL cohort, a non-PCNSL disease-control cohort, and a nested longitudinal cerebrospinal fluid/peripheral blood subcohort.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria for Healthy Controls
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with pathologically confirmed primary central nervous system lymphoma (PCNSL) following biopsy or surgical resection of a brain, spinal cord, or meningeal lesion. Clinical, imaging, pathological, treatment, and outcome data will be collected. Tumor tissue, cerebrospinal fluid, peripheral blood, urine, saliva, and stool will be collected at baseline, as available. Eligible consenting participants without contraindications to lumbar puncture may enter a longitudinal biospecimen subcohort, with contrast-enhanced brain MRI and serial cerebrospinal fluid and peripheral blood collection at postoperative Month 1 and every 3-6 months thereafter.
Drug: High-dose methotrexate-based therapy · Drug: Bruton tyrosine kinase inhibitor-based therapy
Standard-of-care treatment containing high-dose methotrexate as the backbone regimen, administered alone or in combination with other anticancer agents according to the treating physician's judgment and institutional practice. Treatment selection, dose, schedule, combination regimen, and duration are not assigned by the study protocol. Clinical response, recurrence, survival, adverse events, imaging findings, and longitudinal molecular biomarkers will be recorded prospectively.
Standard-of-care treatment containing a Bruton tyrosine kinase inhibitor as a principal therapeutic component, administered alone or in combination with other anticancer agents according to the treating physician's judgment and institutional practice. The specific BTK inhibitor, dose, schedule, combination regimen, and duration are not assigned by the study protocol. Clinical response, recurrence, survival, adverse events, imaging findings, and longitudinal molecular biomarkers will be recorded prospectively.
Baseline data completeness rate
Percentage of enrolled participants with complete required baseline clinical, imaging, pathological, treatment, and biospecimen information in the electronic case report form. The numerator is the number of participants with all protocol-required baseline data; the denominator is the total number of enrolled participants.
Time frame: At baseline, from enrollment through completion of baseline assessments(up to 30 months)
Paired tumor tissue and cerebrospinal fluid sample acquisition rate
Percentage of eligible participants from whom both evaluable tumor tissue and cerebrospinal fluid samples are successfully collected and stored according to the study standard operating procedures.
Time frame: within 1 month after biopsy or surgery (up to 30 months)
Participant follow-up completion rate
Percentage of enrolled participants who complete the protocol-required clinical and imaging follow-up assessments at Month 12 and Month 24. Completion rates will be calculated separately for each time point.
Time frame: from enrollment to follow-up at Month 3, 6, 12, 24 and 36 (up to 36 months)
Adherence to longitudinal cerebrospinal fluid sampling
Percentage of scheduled cerebrospinal fluid collection visits completed among participants enrolled in the longitudinal cerebrospinal fluid/peripheral blood subcohort.
Time frame: Postoperative Month 1 and every 3-6 months thereafter (up to 36 months)
Association between cerebrospinal fluid ctDNA clearance and MRI response
Cerebrospinal fluid circulating tumor DNA status will be classified as cleared or not cleared at postoperative Month 3 and compared with concurrent MRI response categories-complete response, partial response, stable disease, or progressive disease. The association or agreement will be assessed using contingency-table analysis, kappa statistics, and/or receiver operating characteristic analysis, as applicable.
Time frame: 3-6 months after pathological comfirmation (up to 36 months)
Association of baseline and longitudinal ctDNA/cfRNA status with progression-free survival
Progression-free survival will be evaluated according to baseline and longitudinal cerebrospinal fluid or peripheral blood ctDNA/cfRNA status. Progression-free survival is the time from the prespecified index date to radiographic or clinical disease progression or death from any cause, whichever occurs first.
Time frame: From the prespecified index date through Month 3, 6, 12, 24 and 36 (up to 36 months)
Objective response rate
Percentage of evaluable participants achieving complete response or partial response on MRI, summarized according to prespecified baseline tumor multi-omics characteristics.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Best overall response
Best MRI response recorded during follow-up-complete response, partial response, stable disease, or progressive disease-summarized according to baseline tumor multi-omics characteristics.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Progression-free survival
Time from the prespecified index date to radiographic or clinical progression or death from any cause, whichever occurs first, analyzed according to baseline tumor multi-omics characteristics.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Overall survival
Time from the prespecified index date to death from any cause. Participants without a documented death will be censored at the date they were last known to be alive.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Lead time from molecular recurrence detected by cerebrospinal fluid ctDNA to radiographic recurrence
Number of days between the first post-clearance cerebrospinal fluid ctDNA reappearance or prespecified increase in variant allele fraction and the date of MRI-confirmed disease recurrence. Positive values indicate that molecular recurrence preceded radiographic recurrence.
Time frame: Postoperative Month 1 and every 3 months thereafter (up to 36 months)
Concordance and clinical associations of key driver variants in tumor tissue and cerebrospinal fluid
Concordance of key driver variants, including MYD88, between tumor tissue and cerebrospinal fluid ctDNA, and their associations with pathological subtype, treatment regimen, response, progression, and survival.
Time frame: At baseline and every 3-6 months after pathological confirmation (up to 36 months)
Molecular evolution between diagnosis and recurrence
Changes in somatic variants, variant allele fractions, copy-number alterations, transcriptomic features, or other prespecified molecular characteristics between paired diagnostic and recurrence samples.
Time frame: From baseline to the first documented recurrence (up to 36 months)
Change in neurological and performance status
Change from baseline in neurological function and performance status, including Karnofsky Performance Status and/or Eastern Cooperative Oncology Group performance status.
Time frame: At baseline and every 3-6 months thereafter (up to 60 months)
Change in cognitive function
Change from baseline in cognitive function measured using a prespecified validated cognitive assessment instrument.
Time frame: At baseline and every 3 months thereafter (up to 60 months)
Incidence of treatment-related adverse events
Number and percentage of participants experiencing treatment-related adverse events, summarized by event type, severity, and relationship to treatment using a prespecified adverse-event grading system.
Time frame: From enrollment to follow-up (up to 36 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.